author-photo

Ann-Marie E Bröske

Hoffmann-La Roche

6

Papers

64

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (25)
PK/PD mediated dose optimization of emactuzumab, a CSF1R inhibitor, in patients with advanced solid tumors and diffuse-type tenosynovial giant cell tumor.

2020 Clinical Pharmacology & Therapeutics
Show All
- Source
- Cite
- Save
Citations (4)
CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

2019 Blood
Show All
- Source
- Cite
- Save
Citations (12)